NEW YORK – Cellink and Phasefocus have signed a distribution agreement for Livecyte, Phasefocus' high-content live-cell imaging platform, the companies said today. Terms of the agreement were not disclosed.
Livecyte integrates label-free quantitative phase imaging technology with automatic cell tracking algorithms to enable users to automatically characterize growth, morphology, and motility of large populations of cells in 96-well plates.
Cellink said that combining its product portfolio of bioprinters, liquid handlers, and bioinks with LIvecyte will enable researchers to improve workflow efficiencies for applications such as drug discovery, regenerative medicine, and cell-based assays.
"We have taken an important step to better serve our customer base by adding the groundbreaking Livecyte to our growing live cell imaging portfolio," Paul Berning, head of global sales at Cellink, said in a statement.
Sheffield, UK-based Phasefocus "offers a leading technology in quantitative phase imaging," Jonas Schöndube, business area manager at Cellink, said in an email. "The Livecyte will allow our customers to do more in-depth analyses on their label-free living cells and succeed even with the most complex cell tracking tasks."
The geographies covered by the distribution deal were not disclosed. Cellink was founded in Gothenburg, Sweden and is currently headquartered in Boston with offices and distributors worldwide.